Profile data is unavailable for this security.
About the company
PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.
- Revenue in USD (TTM)0.00
- Net income in USD-18.15m
- Incorporated2018
- Employees6.00
- LocationPaxMedica Inc303 South Broadway, Suite 125TARRYTOWN 10591United StatesUSA
- Phone+1 (914) 987-2876
- Fax+1 (302) 636-5454
- Websitehttps://www.paxmedica.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NovAccess Global Inc | 0.00 | -1.74m | 441.57k | 1.00 | -- | -- | -- | -- | -0.1193 | -0.1193 | 0.00 | -0.2246 | 0.00 | -- | -- | 0.00 | -1,836.30 | -2,185.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -177.93 | -- | -- | -- |
| Endonovo Therapeutics Inc | 255.72k | -4.40m | 444.45k | 0.00 | -- | -- | -- | 1.74 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
| Herborium Group, Inc. | 340.33k | -318.65k | 545.97k | 2.00 | -- | -- | -- | 1.60 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
| Drazcanna Inc | 2.05m | -5.71m | 562.15k | -- | -- | -- | -- | 0.2746 | -0.7024 | -0.7024 | 0.2492 | 0.1004 | 0.685 | -- | 23.88 | -- | -191.19 | -- | -643.20 | -- | -11.20 | -- | -279.10 | -- | -- | -33.04 | 0.2445 | -- | -- | -- | -- | -- | -- | -- |
| Capstone Therapeutics Corp | 0.00 | -358.00k | 580.00k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
| GlobeStar Therapeutics Corp | 0.00 | -1.98m | 639.61k | -- | -- | -- | -- | -- | -0.0023 | -0.0023 | 0.00 | -0.0015 | 0.00 | -- | -- | -- | -38,103.72 | -4,657.88 | -- | -- | -- | -7,790.20 | -- | -2,834,410.00 | -- | -21.00 | -- | -- | -- | -- | -31.01 | -- | -- | -- |
| Yield10 Bioscience Inc | 750.00k | -12.70m | 650.59k | 29.00 | -- | -- | -- | 0.8675 | -135.92 | -135.92 | 1.95 | -9.71 | 0.1697 | -- | -- | 25,862.07 | -287.44 | -91.26 | -- | -108.09 | -- | -- | -1,693.60 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
| International Stem Cell Corp | 8.32m | -529.00k | 712.39k | 29.00 | -- | -- | -- | 0.0856 | -0.0661 | -0.0661 | 1.04 | 0.0355 | 1.46 | 2.54 | 11.31 | 286,965.50 | -12.02 | -29.22 | -84.86 | -73.82 | 58.62 | 59.49 | -8.22 | -21.01 | 0.4785 | -3.94 | 0.9254 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
| PaxMedica Inc | 0.00 | -18.15m | 745.47k | 6.00 | -- | 0.6011 | -- | -- | -11.19 | -11.19 | 0.00 | 0.1594 | 0.00 | -- | -- | 0.00 | -474.77 | -755.77 | -781.78 | -- | -- | -- | -- | -- | -- | -3,015.03 | 0.00 | -- | -- | -- | -23.56 | -- | -- | -- |
| VBI Vaccines Inc | 9.41m | -83.99m | 745.74k | 131.00 | -- | -- | -- | 0.0792 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 816.78k | 15.00 | -- | 0.0413 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 899.60k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
| Genprex Inc | 0.00 | -26.14m | 988.82k | 26.00 | -- | 0.2247 | -- | -- | -16.04 | -16.04 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -232.21 | -92.06 | -318.88 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Osaic Wealth, Inc. (Investment Management)as of 30 Jun 2024 | 58.00 | 0.00% |
| Souders Financial Advisors LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Two Sigma Securities LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Tower Research Capital LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| American Portfolios Advisors, Inc.as of 30 Jun 2024 | 0.00 | 0.00% |
| Virtu Americas LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| G1 Execution Services LLCas of 30 Jun 2024 | 0.00 | 0.00% |
